Newsletter

Carna Tech Note No.3: Evaluating Kinase Inhibitors in Binding Assays using Activated and Non-Activated Biotinylated Kinases

9/ 9/21

The simplest and most straightforward way to evaluate a kinase inhibitor is to look at its inhibitory effect on the enzyme activity response. For this to be most useful and accurate, it is critical to establish the appropriate assay condition like ATP concentration and substrate¹). Issues can exist such as the...

Carna Tech Note No.2: The importance of assessing intrinsic target kinase activity

9/ 9/21

Carna Biosciences’ long standing commitment to manufacture highly active protein kinases is based on our belief that drugs designed to inhibit disease related protein dysregulation should be evaluated in activity- based enzyme assays usingthe most active kinases. Nearly all kinases produced at Carna are expressed in insect cells, purified, and...

Carna Tech Note No.1 : Production of Highly Active Protein Kinases for Drug Discovery Applications

9/ 9/21

Carna Biosciences’ long standing commitment to manufacture highly active protein kinases is based on our belief that drugs designed to inhibitdisease related protein dysregulation should be evaluated in activity- based enzyme assays using the most active kinases. Production of proteinkinases meeting these standards is not always an easy task. Despite use...

Targeted Degradation of Non-catalytic Kinases - New Drug Discovery Options ~

9/ 9/21

The announcement that Kymera Therapeutics, a company pioneering targeted protein degradation, entered into a strategic collaboration with Sanofi to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases highlights the growing interest in clinical applications of small molecule mediated kinase degradation. Kymera received $150 million...

Drug-resistant EGFR mutations in lung cancer

7/29/21

Since the clinical introduction of imatinib as a cancer therapeutic in 2001, the development of kinase inhibitors has focused on identification of first-in-class drugs for specific targets. Additionally, the search for next generation drugs targeting drug resistant kinase mutants has greatly expanded, initiating a focus on personalized medicine, particularly in...